



COMPETITION COMMISSION OF INDIA

(Combination Registration No.C-2015/10/331)

03.12.2015

**Notice under sub-section (2) of Section 6 of the Competition Act, 2002 given by
Vidhi Research and Development LLP**

Order under sub-section (1) of Section 31 of the Competition Act, 2002 (“Act”)

CORAM:

Mr. Ashok Chawla
Chairperson

Mr. S. L. Bunker
Member

Mr. Sudhir Mital
Member

Mr. Augustine Peter
Member

Mr. M.S. Sahoo
Member

Mr. U. C. Nahta
Member

Mr. G. P. Mittal
Member

Legal representative: P. H. Bathiya & Associates

1. On 21.10.2015, the Competition Commission of India (“**Commission**”) received a notice given under sub-section (2) of Section 6 of the Act (“**Notice**”), by Vidhi Research and Development LLP (“**Vidhi**” or the “**Acquirer**”). As per the information given in the Notice, the proposed combination relates to the acquisition of a formulations plant of Pfizer Limited (“**Pfizer**”) located at Thane District in



COMPETITION COMMISSION OF INDIA



Fair Competition
For Greater Good

- Maharashtra by Vidhi. For the purpose of the proposed combination, Vidhi and Pfizer entered into a Business Transfer Agreement on 23.09.2015.
2. The proposed combination falls under Section 5(a) of the Act.
 3. In terms of Regulation 14 of the Competition Commission of India (Procedure in regard to the transaction of business relating to combinations) Regulations, 2011, vide letter dated 18.11.2015, the Acquirer was required to remove certain defects and provide certain information, the response to which was received on 19.11.2015.
 4. Vidhi is a limited liability partnership incorporated in India, on 15.09.2014. As per the information given in the Notice, Vidhi has not started any operation from the date of its incorporation. Pfizer is a company registered in India and is stated to be engaged in manufacture and sale of pharmaceutical and consumer healthcare products in India.
 5. As already stated, the proposed combination relates to acquisition of the formulations plant of Pfizer at Thane District in Maharashtra. In this regard, it has been submitted that there have been no commercial operations (including R&D operations) at the said plant since the year 2013. It is further observed from the information given in the Notice that the partners of Vidhi and entities controlled by them do not hold any significant investments in the pharmaceutical sector which may result in any competition concern.
 6. Considering the facts on record and the details provided in the Notice given under sub-section (2) of Section 6 of the Act and the assessment of the combination after considering the relevant factors mentioned in sub-section (4) of Section 20 of the Act, the Commission is of the opinion that the combination is not likely to have any appreciable adverse effect on competition in India and therefore, the Commission hereby approves the combination under sub-section (1) of Section 31 of the Act.



COMPETITION COMMISSION OF INDIA



**Fair Competition
For Greater Good**

7. This order shall stand revoked if, at any time, the information provided by the Acquirer is found to be incorrect.

8. The Secretary is directed to communicate to the Acquirer accordingly.